md-medicaldata

Authors

 

Danijela Đurić-Petković¹, Elizabeta Ristanović², Nada Kuljić-Kapulica<sup>2

1</sup>Institut za mikrobiologiju,
²Vojnomedicinska akademija, Beograd

 

Rad je primljen 20.06.2017. / Prihvaćen 20.08.2017.

 

Correspondence to

Dr Danijela Đurić Petković,
Institut za mikrobiologiju, Vojnomedicinska akademija
Mob. tel. 063440482
e-mail: danijeladjuricpetkovic@gmail.com

 

 

Sažetak

 

Male boginje su vrlo zarazna bolest uzrokovana virusom malih boginja i jedna od tipičnih virusnih bolesti dece. Uprkos dostupnosti efikasne i sigurne vakcine ova bolest je i dalje jedan od vodećih uzroka smrti kod dece širom sveta. Virus malih boginja pripada rodu Morbillivirus, familiji Paramyxoviridae. Genom mu čini negativna, jednolančana, nesegmentirana RNK. Prirodni domaćin virusa je čovek. Simptomi su povišena temperatura, kašalj, curenje nosa, konjuktivitis i generalizovana makulopapularna ospa. Patognomoničan znak za male boginje su Koplikove mrlje.Infekcija može dovesti do teških, nekada i fatalnih komplikacija.Retka ali fatalna posledica je subakutni sklerozirajući panencefalitis. Nema specifične antivirusne terapije.Jedina efikasna mera protiv malih boginja je imunizacija. Iskorenjivanje bolesti u bliskoj budućnosti nije izvesno. Da bi se postigao ovaj cilj i da bi se zaustavio prenos virusa u endemskim područjima više od 95% populacije mora biti uspešno vakcinisano.

 

 

 

Ključne reči:

male boginje, komplikacije, terapija, eradikacija,vakcinacija

 

 

Abstract

 

Measles is a highly contagious disease caused by measles virus (MeV) and one of the typical viral diseases of childhood. The disease remains one of the leading causes of death among young children globally, despite the availability of a safe and effective vaccine. MeV belongs to the genus Morbillivirus, family Paramyxoviridae. Genom is a single-stranded, negative-sense, non-segmented RNA. The natural hosts of the virus is man. Symptoms include fever, cough, runny nose, conjuctivitis and a generalized, maculopapular rash. Koplik's spots are pathognomonic sign of measles. Infection can lead to serious and even fatal complications. A rare, but fatal long-term consequence is subacute sclerosing panencephalitis. There is no specific antiviral treatment. Immunisation is the only effective preventive measure against measles. Disease eradication doesn't seem likely in the near future. To reach this aim and to stop endemic MeV transmission more than 95 % of a population must be successfully vaccinated.

 

 

Key words:

measles, complications, therapy, eradication, vaccination

 

 

References

 

1. Otri AM, Singh AD, Dua HS. "Abu Bakr Razi". The British Journal of Ophthalmology. 2008; 92 (10): 1324.
2. Silverstein, Arthur M. "Clemens Freiherr von Pirquet: Explaining immune complex disease in 1906." Nature Immunology. 2000;  1(6) : 453-55.
3. Enders JF, Peebles TC.” Propagation in tissue cultures of cytopathogenic agents from patients with measles”. Proc Soc Exp Biol Med. 1954; 2:277-86. PMID 13177653.
4. Andreas.O, Obojes.K, Kim KS, tel Meulen V, Scneider-Schaulies J. “CD46 and CD150- independent endothelial cell infection with wild-type measles viruses”. J Gen Virol. 2003;  84: 1189-97.
5. Yanagi Y.,Takeda M.  and Ohno S.”Measles virus: cellular receptors, tropism and pathogenesis”. J Gen Virol. 2006; 87 : 2767-79.
6. Faruse Y., Suzuki A., Oshitani H.”Origin of measles virus: divergence from rinderpest virus between the 11th and 12th centuries”. Virology Journal.2010; 7:52 ,DOI: 10.1186/1743-422X-7-52.
7. https://www.cdc.gov/measles/lab-tools/genetic-analysis.html
8. D.M.Knipe ,P.M. Howley. Fields Virology 6th ed. Philadelphia: Lippincot Wiliams & Wilkins, a Wolters Kluwer business. 2007; 1042-66.
9. https://ecdc.europa.eu/en/news-events/epidemiological-update-measles-monitoring-european-outbreaks-7-july-2017.
10. Beckford AP, Kaschula ROC, Stephen C. “Factors associated with fatal cases of measles: a retrospective autopsy study”. S Afr Med J.1985; 68: 858–63.
11. Jabbour JT, Duenas DA, Sever JL, et al. “Epidemiology of subacute sclerosing panencephalitis: a report of the SSPE registry”. JAMA. 1972; 220:959–62.
12. Rima BK, Duprex WP. “Molecular mechanisms of measles virus persistence” .Virus Res. 2005; 111: 132–47.
13. Hotta H., Nihei K., Abe Y., Kato S., Jiang DP., Nagano-Fujii M., Sada K. “Full-length sequence analysis of subacute sclerosing panencephalitis (SSPE) virus, a mutant of measles virus, isolated from brain tissues of a patient shortly after onset of SSPE”. Microbiol Immunol. 2006; 50(7) :525-34.
14. Rammohan KW., McFarland HF., McFarlin DE. “Subacute sclerosing panencephalitis after passive immunization and natural measles infection: role of antibody in persistence of measles virus”. Neurology. 1982 ;32 :390–394.
15. Fujinami RS., Oldstone MBA. “Antiviral antibody reacting on the plasma membrane alters measles virus expression inside the cell”. Nature. 1979; 279: 529–530.
16. Rusell S.J. and Peng K.W. “ Measles virus for cancer therapy”. Curr Top Microbiol Immunol.2009; 330: 213-41.

UDK: 616.615
578.831
COBISS.SR-ID 245430796

PDF Đurić-Petković D. at al. • MD-Medical Data 2017;9(3): 181-184